Cayman Pnu 282987; Purity- Greater Than Or Equal To 98%; Size- 10

JNJ-31020028 is a brain-permeable selective antagonist of the neuropeptide Y (NPY) receptor Y₂ (IC₅₀s = 8.51, 6.03, and 6.17 nM for human, rat, and mouse receptors, respectively) with over 100-fold selectivity for Y₂ over Y₁, Y₄, and Y₅ receptors.^, JNJ-31020028 inhibits calcium release induced by peptide YY in a functional assay in KAN-TS cells (pK_B = 8.04) and blocks NPY(13-36)-induced decreases in twitch contraction amplitude in isolated rat vas deferens (IC₅₀ = 7.94 nM). Administration of JNJ-31020028 to rats during abstinence (20 mg/kg per day, i.p.) reverses nicotine-induced social anxiety-like behavior and increases hippocampal Y₂ receptor mRNA levels. It reverses withdrawal-induced anxiety-like behavior in rats in the elevated plus maze following a single bolus dose of alcohol when administered at a dose of 15 mg/kg. In an olfactory bulbectomized rat model of depression, chronic JNJ-31020028 treatment (10 nmol per day, i.c.v.) decreases immobility time in the forced swim test but has no effect in control animals.

WARNING This product is not for human or veterinary use.